<?xml version="1.0" encoding="UTF-8"?>
<ref id="B68-pharmaceuticals-13-00096">
 <label>68.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kubo</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Nakayamada</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Nakano</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Tanaka</surname>
    <given-names>Y.</given-names>
   </name>
  </person-group>
  <article-title>THU0203 baricitinib targets the type I IFN/STAT-medicated activities of human T cells and dendritic cells</article-title>
  <source>Ann. Rheum. Dis.</source>
  <year>2016</year>
  <volume>75</volume>
  <fpage>260</fpage>
  <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-eular.2222</pub-id>
  <pub-id pub-id-type="pmid">25344431</pub-id>
 </element-citation>
</ref>
